Abstract: A one-bead-two-compound combinatorial synthesis technique provides libraries of macrocyclic peptidomimetic compounds and compositions with use as ligands for the Ephrin type-A receptor 2 (EphA2). The one-bead-two-compound technique and libraries of macrocyclic compounds are useful as research tools in drug discovery and/or to treat or prevent a range of diseases or disorders.
Abstract: The present invention provides (+)-morphinans comprising Toll-like receptor 9 (TLR9) antagonist activity, as well as methods for using the (+)-morphinans to treat pain. Also provided are pharmaceutical combination compositions comprising a (+)-morphinan and an opioid agonist/monoamine reuptake inhibitor, as well as methods for using the combination compositions to treat pain.
Abstract: The present invention relates to compounds according to general formula (I) which are analogues of epoxymetabolites produced by cytochrome P450 (CYP) enzymes from omega-3 (n-3) polyunsaturated fatty acids (PUFAs). The present invention further relates to compositions containing one or more of these compounds and to the use of these compounds or compositions for the treatment or prevention of conditions and diseases associated with inflammation, proliferation, hypertension, coagulation, immune function, pathologic angiogenesis, heart failure and cardiac arrhythmias.
Type:
Grant
Filed:
January 21, 2015
Date of Patent:
September 28, 2021
Inventors:
Wolf-Hagen Schunck, Dominik Mueller, Robert Fischer, Gerd Wallukat, Anne Konkel, John Russell Falck
Abstract: Provided here are nitric oxide-releasing compounds that include at least two different NO donor functional groups of the same class. In some embodiments, such nitric oxide-releasing compounds are macromolecules such as dendrimer and co-condensed silica. Pharmaceutical compositions, wound dressings, kits and methods of treatments are also provided herein.
Type:
Grant
Filed:
August 29, 2019
Date of Patent:
September 21, 2021
Assignees:
Novan, Inc., The University of North Carolina at Chapel Hill
Inventors:
Mark Schoenfisch, Yuan Lu, Nathan Stasko, Jian Bao
Abstract: Disclosed are compounds that promote spinogenesis, are capable of reducing the neural toxicity of beta-amyloid peptides, and/or reduce the symptoms of traumatic brain injury in a patient.
Type:
Grant
Filed:
August 1, 2018
Date of Patent:
September 14, 2021
Assignee:
Spinogenix, Inc.
Inventors:
Stella Sarraf, Vincent F. Simmon, Gerald F. Swiss
Abstract: Provided herein are methods of identifying the origin of a nucleic acid sample. The methods include forming a reaction mixture comprising a nucleic acid sample comprising nucleic acid molecules from a single cell and a set of barcodes, incorporating the set of barcodes into the nucleic acid molecules of the sample, and identifying the set of barcodes incorporated into the nucleic acid molecules of the single cell thereby identifying the origin of the nucleic acid sample.
Abstract: The present invention relates to methods for high multiplex protein or cellular constituent analysis in single cells or single isolated aggregations of cellular constituents. The methods provide for embedding cells or isolated aggregations of cellular constituents in a hydrogel mesh and labeling of cellular constituents with labeling ligands linked to a nucleic acid tag. Cellular constituents can be determined using sequencing methods.
Type:
Grant
Filed:
October 27, 2016
Date of Patent:
August 17, 2021
Assignees:
The Board Institute, Inc., Massachusetts Institute of Technology
Abstract: Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating conditions associated with modulation of UBE2K.
Type:
Grant
Filed:
December 31, 2020
Date of Patent:
August 17, 2021
Assignee:
Berg LLC
Inventors:
Vivek K. Vishnudas, Dinesh U. Chimmanamada, Santosh A. Khedkar
Abstract: The present invention relates to a compound of formula (I), or a tautomer and/or a pharmaceutically acceptable salt thereof, and its uses to treat a disorder associated with protein misfolding stress and in particular with an accumulation of misfolded proteins.
Abstract: Disclosed herein are expression vectors which display a passenger polypeptide on the outer surface of a biological entity. As disclosed herein the displayed passenger polypeptide is capable of interacting or binding with a given ligand. Also disclosed are methods of making and using the expression vectors. N/C terminal fusion expression vectors and methods of making and using are also disclosed.
Type:
Grant
Filed:
December 11, 2019
Date of Patent:
August 3, 2021
Assignee:
The Regents of the University of California
Inventors:
Patrick S. Daugherty, Paul H. Bessette, Jeffrey Rice
Abstract: Methods, compositions, and kits comprising target-specific oligonucleotides (TSOs) are disclosed herein. Methods, compositions, and kits comprising target-specific oligonucleotides (TSOs) can be used to attach adapters and/or linkers to target RNAs. Methods, compositions, and kits comprising target-specific oligonucleotides (TSOs) can be used in reactions, including, but not limited to, ligation reactions, amplification reactions, and sequencing reactions. Additionally, methods, compositions, and kits comprising target-specific oligonucleotides (TSOs) can be used for reducing and/or preventing the formation of secondary structures in target RNAs. These methods, compositions, and kits can also find use in a number of applications, for example, any application that benefits from stabilizing primary RNA structure, such as detecting and quantifying target RNAs in a sample, in the construction of small RNA libraries, in microarray and RT-qPCR applications, etc.
Abstract: Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.
Type:
Grant
Filed:
January 2, 2020
Date of Patent:
July 20, 2021
Assignee:
CAYMAN CHEMICAL COMPANY, INC.
Inventors:
Stephen Douglas Barrett, Fred Lawrence Ciske, Joseph Michael Colombo, Gregory William Endres, Bradlee David Germain, Andriy Kornilov, James Bernard Kramer, Adam Uzieblo, Kirk M. Maxey
Abstract: Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-?4?7 integrin antibody such as vedolizumab. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-?4?7 integrin antibody.
Type:
Grant
Filed:
May 14, 2020
Date of Patent:
June 29, 2021
Assignee:
ChemoCentryx, Inc.
Inventors:
James Campbell, Israel Charo, Thomas Schall
Abstract: Systems, kits, and methods for detecting and quantifying proteomic activity using DNA-encoded probes are provided, where the proteomic activity may be enzymatic activity or ligand binding affinity. Such systems and methods encode quantitative proteomic activity information into DNA sequence populations and utilize DNA-linked substrates or ligands as activity probes. The systems, kits, and methods that are directed to detecting ligand affinity further include crosslinking steps to ensure the integrity of the DNA-linked ligands during purification and washing. Signal detection involves the chemical manipulation of a probe population downstream of sample exposure and application of purifying, selective pressure for desired products. Selection-induced changes in DNA abundance between the initial pool and the purified pool indicate sample activity.
Type:
Grant
Filed:
August 18, 2016
Date of Patent:
June 8, 2021
Assignee:
Purdue Research Foundation
Inventors:
Casey J. Krusemark, Kyle E. Denton, Dongwook Kim, Rachael R. Jetson
Abstract: Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-?4?7 integrin antibody such as vedolizumab. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-?4?7 integrin antibody.
Type:
Grant
Filed:
December 9, 2019
Date of Patent:
June 1, 2021
Assignee:
ChemoCentryx, Inc.
Inventors:
Yibin Zeng, Penglie Zhang, Thomas Schall, Israel Charo, James J. Campbell
Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.
Type:
Grant
Filed:
December 21, 2018
Date of Patent:
May 11, 2021
Assignee:
Board of Regents, The University of Texas System
Inventors:
Philip Jones, Maria Emilia Di Francesco, Alessia Petrocchi, Christopher L. Carroll, Joe Marszalek, Barbara Czako, Ryan Johnson, Jay Theroff
Abstract: Disclosed are a variety of amphoteric ester sulfonates, including 3-(N, N-dimethyl-cocoylpropylammonio-1-yl)-2-hydroxypropanesulfonate. These amphoteric ester sulfonates can be advantageously prepared in high yield and purity by a two-step chemoenzymatic process, and have excellent surfactant properties.
Type:
Grant
Filed:
March 1, 2018
Date of Patent:
May 11, 2021
Assignee:
Eastman Chemical Company
Inventors:
Neil Warren Boaz, Matthew Allen Boone, Jennifer Michelle Lloyd
Abstract: Provided herein are compositions and methods for generating phase-shift barcode oligonucleotides for library construction for next-generation sequencing. In some cases, barcode oligonucleotides are attached to particles or beads. Also provided are methods and kits for using the phase-shift barcode oligonucleotides in sequencing assays.
Abstract: In some aspects, the invention relates to a method for producing a barcoded DNA library, comprising: optionally fragmenting DNA to produce fragmented DNA; combining the DNA/fragments with control nucleotide sequences to produce a mixture of nucleic acids, each control nucleotide sequence comprising a variable nucleotide sequence, thereby barcoding the DNA/fragments; amplifying the mixture of nucleic acids to produce amplified nucleic acids; isolating a plurality of nucleic acids from the amplified nucleic acids; and rearranging the nucleic acids of the plurality, thereby producing the barcoded DNA library.
Type:
Grant
Filed:
February 19, 2016
Date of Patent:
April 27, 2021
Assignee:
The Regents of the University of California
Inventors:
Sriram Kosuri, Rocky Cheung, Nathan B. Lubock